| 0.1117 0.004 (3.33%) | 06-10 10:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.45 | 1-year : | 0.69 |
| Resists | First : | 0.39 | Second : | 0.59 |
| Pivot price | 0.11  |
|||
| Supports | First : | 0.06 | Second : | 0.05 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.11 |
| MA(100) : | 0.26 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.2 |
D(3) : | 30.6 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 6.42 | Low : | 0.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ POM ] has closed above bottom band by 43.6%. Bollinger Bands are 80.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.12 - 0.12 | 0.12 - 0.12 |
| Low: | 0.1 - 0.1 | 0.1 - 0.1 |
| Close: | 0.11 - 0.11 | 0.11 - 0.11 |
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Tue, 09 Jun 2026
POMDOCTOR LIMITED SPON ADS EACH REP 0.16 CL A (POM) Revenue Breakdown - Main Composition - Moomoo
Mon, 08 Jun 2026
POM Stockholder Alert: Robbins LLP Reminds Investors of the Clas - GuruFocus
Fri, 29 May 2026
POM Should I Buy - Intellectia AI
Thu, 14 May 2026
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results - Yahoo Finance
Mon, 13 Apr 2026
POM Deadline: POM Investors with Losses in Excess of $100K Have Opportunity to Lead PomDoctor Ltd. Securities Fraud Lawsuit - Morningstar
Fri, 10 Apr 2026
Bronstein, Gewirtz & Grossman LLC Urges PomDoctor, Ltd. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 122 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 1,220 (K) |
| Shares Short P.Month | 234 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -9.08 |
| Profit Margin | -53.2 % |
| Operating Margin | -46.7 % |
| Return on Assets (ttm) | -94.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 0.42 |
| Sales Per Share | 3.27 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -148 (M) |
| Levered Free Cash Flow | -119 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | -0.02 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -0.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|